E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
anamnestic immune response in healthy 4 to 7 year-old children previously vaccinated at about 3, 5 and 11 to 13 months of age |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054130 |
E.1.2 | Term | Hepatitis B immunisation |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Immunogenicity To describe in subjects vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX-HEXA during the first two years of life the percentage of subjects with an anti-HBs antibody titre ≥10 mIU/mL (i.e. seroprotection rate) 1 month after a booster dose (4th dose of a Hepatitis B vaccine) of either HBVaxPRO 5 μg or ENGERIX-B 10 μg. |
|
E.2.2 | Secondary objectives of the trial |
Immunogenicity To describe in subjects vaccinated with 3 doses of HEXAVAC or 3 doses of INFANRIX-HEXA during the two first years of life: - The percentage of subjects with anti-HBs antibody titres ≥100 mIU/mL at 1 month post-booster dose (4th dose of a Hepatitis B vaccine) of each of either HBVAXPRO 5 µg or ENGERIX-B 10 µg. - The anti-HBs antibody titres at each time-point. - The percentage of subjects with anti-HBs antibody titres ≥10 mIU/mL and ≥100 mIU/mL and the anti-HBs antibody titres at 1 month post-booster dose (4th dose of a Hepatitis B vaccine) of either HBVAXPRO 5 µg or ENGERIX-B 10 µg according to the pre-booster anti-HBs antibody titres. Safety To describe the safety profile of each of both HBVAXPRO 5 µg and ENGERIX-B 10 µg when administered as a booster dose (4th dose of a Hepatitis B vaccine |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Healthy child of either gender, 2. Child of 4 to 7 years of age (from the first day of the 4th birthday to one day prior to the 8th birthday) 3. Groups 1A and 1B: Child vaccinated with 2 doses of HEXAVAC during the first 6 months of life and with a 3rd dose of HEXAVAC during the second year of life (documented vaccination history), or Groups 2A and 2B: Child vaccinated with 2 doses of INFANRIX-HEXA during the first 6 months of life and with a 3rd dose of INFANRIX-HEXA during the second year of life (documented vaccination history), 4. Informed consent form signed by the parent(s) or by the legal representative according to the local regulations. 5. Parent(s) or legal representative able to attend all scheduled visits with the subject and to understand and comply with the study procedures (i.e. able to read and write). |
|
E.4 | Principal exclusion criteria |
1- Any recent (equal or less than 3 days) history of febrile illness (rectal temperature equal or greater than 38.0C or oral temperature ≥37.5C), 2- Receipt of more than 3 doses of any Hepatitis B containing vaccine, either alone or in any combination, 3- History of clinical or serological-confirmed diagnosis of infection due to hepatitis B, 4- History or current close contact with known carriers of hepatitis B virus, 5- Prior known sensitivity/allergy to any component of the study vaccines, 6- Any known blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems, 7- Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection, 8- Any immune impairment or humoral/cellular deficiency or depressed immunity, 9- Any recent (eual or less than 30 days) long-term (equal or more than 14 days) administration of systemic corticosteroid therapy given daily or on alternate days at high doses (more or qgual to 20mg/day) or scheduled administration through Visit 2, 10- Any receipt (eual or less than 3 months) of immune globulin or blood-derived product, or scheduled administration through Visit 2, 11- Any recent (equal or less than 14 days) receipt of an inactivated vaccine or scheduled administration through Visit 2, 12- Any recent (equal or less than 28 days) receipt of a live vaccine or scheduled administration through Visit 2 13- Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives, 14- Subject that, in the investigators opinion, is likely to be lost to follow-up or to be poorly compliant with the study requirements, 15- Planned participation in another clinical study during the present study period. Second part of the study only: Investigators are recommended to defer/reschedule vaccination if any of the following conditions is true: 1. Febrile illness (rectal temperature equal or greater than 38.0C or oral temperature ≥37.5C) within 3 days prior to vaccination, 2. Current immunosuppressive therapy (including systemic corticosteroids given daily or on alternate days at equal or more than 20 mg/day prednisone equivalent during 14 days or more in the previous 30 days) 3. Receipt of immunoglobulins or blood-derived products within the previous 3 months 4. Receipt of an inactivated vaccine within the previous 14 days 5. Receipt of a live vaccine within the past 28 days. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
This study is a descriptive study. The data will be summarised and no particular formal hypothesis will be tested. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
ultima visita dell'ultimo soggetto inserito nella sperimentazione |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |